Research ExplorerPublicationsNeoadjuvant Chemotherapy of Patients with Early Breast Cance...

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow

Standard

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. / Volmer, Léa; Koch, André; Matovina, Sabine; Dannehl, Dominik; Weiss, Martin; Welker, Ganna; Hahn, Markus; Engler, Tobias; Wallwiener, Markus; Walter, Christina Barbara; Oberlechner, Ernst; Brucker, Sara Yvonne; Pantel, Klaus; Hartkopf, Andreas.

In: CANCERS, Vol. 14, No. 3, 635, 27.01.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Volmer, L, Koch, A, Matovina, S, Dannehl, D, Weiss, M, Welker, G, Hahn, M, Engler, T, Wallwiener, M, Walter, CB, Oberlechner, E, Brucker, SY, Pantel, K & Hartkopf, A 2022, 'Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow', CANCERS, vol. 14, no. 3, 635. https://doi.org/10.3390/cancers14030635

APA

Volmer, L., Koch, A., Matovina, S., Dannehl, D., Weiss, M., Welker, G., Hahn, M., Engler, T., Wallwiener, M., Walter, C. B., Oberlechner, E., Brucker, S. Y., Pantel, K., & Hartkopf, A. (2022). Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. CANCERS, 14(3), [635]. https://doi.org/10.3390/cancers14030635

Vancouver

Volmer L, Koch A, Matovina S, Dannehl D, Weiss M, Welker G et al. Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. CANCERS. 2022 Jan 27;14(3). 635. https://doi.org/10.3390/cancers14030635

Bibtex

@article{fe752eb58446439592cd8843d0d0753d,
title = "Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow",
abstract = "Preclinical data suggest that neoadjuvant chemotherapy (NAT) may promote micrometastatic spread. We aimed to compare the detection rate and prognostic relevance of disseminated tumor cells (DTCs) from the bone marrow (BM) of patients with early-stage breast cancer (EBC) after NAT with that of therapy-naive EBC patients. DTCs were identified from BM samples, collected during primary surgery. Patients who received NAT were compared to patients who received chemotherapy after surgery. In total, 809 patients were analyzed. After NAT, 45.4% of patients were DTC-positive as compared to 19.9% of patients in the adjuvant chemotherapy group (p < 0.001). When sampled in patients who had undergone NAT, the detection of DTCs in the BM was significantly increased (OR: 3.1; 95% confidence interval (CI): 2.1-4.4; p < 0.001). After NAT, DTC-positive patients with ≥2 DTCs per 1.5 × 106 mononuclear cells in their BM had an impaired disease-free survival (HR: 4.8, 95% CI: 0.9-26.6; p = 0.050) and overall survival (HR: 4.2; 95% CI: 1.4-12.7; p = 0.005). The higher rate of DTC-positive patients after NAT as compared to a treatment-naive comparable control cohort suggests that NAT supports tumor cell dissemination into the bone marrow. DTC positivity in BM predicted relapse in various distant organs, implying that tumor cell dissemination was not restricted to the bone marrow.",
author = "L{\'e}a Volmer and Andr{\'e} Koch and Sabine Matovina and Dominik Dannehl and Martin Weiss and Ganna Welker and Markus Hahn and Tobias Engler and Markus Wallwiener and Walter, {Christina Barbara} and Ernst Oberlechner and Brucker, {Sara Yvonne} and Klaus Pantel and Andreas Hartkopf",
year = "2022",
month = jan,
day = "27",
doi = "10.3390/cancers14030635",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

RIS

TY - JOUR

T1 - Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow

AU - Volmer, Léa

AU - Koch, André

AU - Matovina, Sabine

AU - Dannehl, Dominik

AU - Weiss, Martin

AU - Welker, Ganna

AU - Hahn, Markus

AU - Engler, Tobias

AU - Wallwiener, Markus

AU - Walter, Christina Barbara

AU - Oberlechner, Ernst

AU - Brucker, Sara Yvonne

AU - Pantel, Klaus

AU - Hartkopf, Andreas

PY - 2022/1/27

Y1 - 2022/1/27

N2 - Preclinical data suggest that neoadjuvant chemotherapy (NAT) may promote micrometastatic spread. We aimed to compare the detection rate and prognostic relevance of disseminated tumor cells (DTCs) from the bone marrow (BM) of patients with early-stage breast cancer (EBC) after NAT with that of therapy-naive EBC patients. DTCs were identified from BM samples, collected during primary surgery. Patients who received NAT were compared to patients who received chemotherapy after surgery. In total, 809 patients were analyzed. After NAT, 45.4% of patients were DTC-positive as compared to 19.9% of patients in the adjuvant chemotherapy group (p < 0.001). When sampled in patients who had undergone NAT, the detection of DTCs in the BM was significantly increased (OR: 3.1; 95% confidence interval (CI): 2.1-4.4; p < 0.001). After NAT, DTC-positive patients with ≥2 DTCs per 1.5 × 106 mononuclear cells in their BM had an impaired disease-free survival (HR: 4.8, 95% CI: 0.9-26.6; p = 0.050) and overall survival (HR: 4.2; 95% CI: 1.4-12.7; p = 0.005). The higher rate of DTC-positive patients after NAT as compared to a treatment-naive comparable control cohort suggests that NAT supports tumor cell dissemination into the bone marrow. DTC positivity in BM predicted relapse in various distant organs, implying that tumor cell dissemination was not restricted to the bone marrow.

AB - Preclinical data suggest that neoadjuvant chemotherapy (NAT) may promote micrometastatic spread. We aimed to compare the detection rate and prognostic relevance of disseminated tumor cells (DTCs) from the bone marrow (BM) of patients with early-stage breast cancer (EBC) after NAT with that of therapy-naive EBC patients. DTCs were identified from BM samples, collected during primary surgery. Patients who received NAT were compared to patients who received chemotherapy after surgery. In total, 809 patients were analyzed. After NAT, 45.4% of patients were DTC-positive as compared to 19.9% of patients in the adjuvant chemotherapy group (p < 0.001). When sampled in patients who had undergone NAT, the detection of DTCs in the BM was significantly increased (OR: 3.1; 95% confidence interval (CI): 2.1-4.4; p < 0.001). After NAT, DTC-positive patients with ≥2 DTCs per 1.5 × 106 mononuclear cells in their BM had an impaired disease-free survival (HR: 4.8, 95% CI: 0.9-26.6; p = 0.050) and overall survival (HR: 4.2; 95% CI: 1.4-12.7; p = 0.005). The higher rate of DTC-positive patients after NAT as compared to a treatment-naive comparable control cohort suggests that NAT supports tumor cell dissemination into the bone marrow. DTC positivity in BM predicted relapse in various distant organs, implying that tumor cell dissemination was not restricted to the bone marrow.

U2 - 10.3390/cancers14030635

DO - 10.3390/cancers14030635

M3 - SCORING: Journal article

C2 - 35158902

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 3

M1 - 635

ER -